- Home
- DFDV vs CRDF Comparison
DFDV vs CRDF Comparison
Compare DFDV & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DFDV
- CRDF
- Stock Information
- Founded
- DFDV 2018
- CRDF 1999
- Country
- DFDV United States
- CRDF United States
- Employees
- DFDV N/A
- CRDF N/A
- Industry
- DFDV Finance: Consumer Services
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DFDV Finance
- CRDF Health Care
- Exchange
- DFDV Nasdaq
- CRDF Nasdaq
- Market Cap
- DFDV 143.9M
- CRDF 169.6M
- IPO Year
- DFDV N/A
- CRDF N/A
- Fundamental
- Price
- DFDV $14.29
- CRDF $3.62
- Analyst Decision
- DFDV
- CRDF Strong Buy
- Analyst Count
- DFDV 0
- CRDF 4
- Target Price
- DFDV N/A
- CRDF $12.25
- AVG Volume (30 Days)
- DFDV 2.1M
- CRDF 886.0K
- Earning Date
- DFDV 06-17-2025
- CRDF 05-08-2025
- Dividend Yield
- DFDV N/A
- CRDF N/A
- EPS Growth
- DFDV N/A
- CRDF N/A
- EPS
- DFDV N/A
- CRDF N/A
- Revenue
- DFDV $1,975,695.00
- CRDF $587,000.00
- Revenue This Year
- DFDV N/A
- CRDF N/A
- Revenue Next Year
- DFDV N/A
- CRDF N/A
- P/E Ratio
- DFDV N/A
- CRDF N/A
- Revenue Growth
- DFDV 1.47
- CRDF N/A
- 52 Week Low
- DFDV $0.48
- CRDF $2.01
- 52 Week High
- DFDV $53.88
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- DFDV N/A
- CRDF 70.50
- Support Level
- DFDV N/A
- CRDF $2.81
- Resistance Level
- DFDV N/A
- CRDF $3.84
- Average True Range (ATR)
- DFDV 0.00
- CRDF 0.22
- MACD
- DFDV 0.00
- CRDF 0.08
- Stochastic Oscillator
- DFDV 0.00
- CRDF 80.00
About DFDV DeFi Development Corp. Common Stock
DeFi Development Corp is an AI-powered online platform that connects the commercial real estate industry by providing data and software subscriptions as well as value-add services to multifamily and commercial property professionals.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.